NCT00384826

Therapeutic Strategy in Advanced Bronchioloalveolar Carcinoma

Effect of an Early Therapeutic Permutation on the Tumoral Control of Patients Receiving in First Line a Specific Inhibitor of Tyrosin Kinase of EGFR (Erlotinib) or a Taxan-based Chemotherapy for the Treatment of Not Resecable Adenocarcinoma With Bronchiolo-alveolar.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 133 (actual)
• Sponsor: Intergroupe Francophone de Cancerologie Thoracique · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate among patients with untreated advanced ADC-CBA, impact on the disease control rate after 4 months treatment of an early therapeutic permutation with the first month in the absence of stabilization or objective answer.

Conditions

• Adenocarcinoma, Bronchiolo-Alveolar

Interventions

Type	Name	Description
DRUG	erlotinib	Erlotinib 150 mg/day (until progression)
DRUG	paclitaxel + carboplatine	Paclitaxel 90 mg/m² D1, D8, D15 (D1=D28, until progression) Carboplatine AUC 6 D1 (D1=D28, 6 cycles)

Timeline

• Start date: 2006-09-01
• Primary completion: 2014-02-01
• Completion: 2014-02-01
• First posted: 2006-10-06
• Last updated: 2015-02-16

Locations

9 sites across 1 country: France